Cargando…

Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors

In cancer-immunity cycle, the immune checkpoint PD1 and its ligand PDL1 act as accomplices to help tumors resist to immunity-induced apoptosis and promote tumor progression. Immunotherapy targeting PD1/PDL1 axis can effectively block its pro-tumor activity. Anti-PD1/PDL1 therapy has achieved great s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lei, Qingyang, Wang, Dan, Sun, Kai, Wang, Liping, Zhang, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Cell and Developmental Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385189/ https://www.ncbi.nlm.nih.gov/pubmed/32793604 http://dx.doi.org/10.3389/fcell.2020.00672

Ejemplares similares

Integration of cancer stemness and neoantigen load to predict responsiveness to anti-PD1/PDL1 therapy
por: Luo, Kunpeng, et al.
Publicado: (2022)

Expression profile of miRNAs computationally predicted to target PDL-1 in cervical tissues of different histology groups
por: Leventakou, Danai, et al.
Publicado: (2023)

MHC-II Signature Correlates With Anti-Tumor Immunity and Predicts anti-PD-L1 Response of Bladder Cancer
por: Yi, Ruibin, et al.
Publicado: (2022)

Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies
por: Zhou, Kaijian, et al.
Publicado: (2020)

Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma
por: Fu, Yuyin, et al.
Publicado: (2021)

Universal cutoff for tumor mutational burden in predicting the efficacy of anti-PD-(L)1 therapy for advanced cancers
por: Mo, Shu-Fen, et al.
Publicado: (2023)

Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti–PD-1 Therapy
por: Fan, Xiaona, et al.
Publicado: (2021)

Anti-Tumor Necrosis Factor Receptor 2 Antibody Combined With Anti-PD-L1 Therapy Exerts Robust Antitumor Effects in Breast Cancer
por: Fu, Qiang, et al.
Publicado: (2021)

Differential Role of PD-1 Expressed by Various Immune and Tumor Cells in the Tumor Immune Microenvironment: Expression, Function, Therapeutic Efficacy, and Resistance to Cancer Immunotherapy
por: Kim, Myeong Joon, et al.
Publicado: (2021)

Editorial: Tumor Microenvironment and Cancer Cell Interactions in Solid Tumor Growth and Therapy Resistance
por: Ruocco, Maria Rosaria, et al.
Publicado: (2022)

MicroRNA-138-5p Suppresses Non-small Cell Lung Cancer Cells by Targeting PD-L1/PD-1 to Regulate Tumor Microenvironment
por: Song, Nannan, et al.
Publicado: (2020)

Identification of an Immune-Related Risk Signature Correlates With Immunophenotype and Predicts Anti-PD-L1 Efficacy of Urothelial Cancer
por: Li, Pengju, et al.
Publicado: (2021)

LncRNA KCNQ1OT1 Secreted by Tumor Cell-Derived Exosomes Mediates Immune Escape in Colorectal Cancer by Regulating PD-L1 Ubiquitination via MiR-30a-5p/USP22
por: Xian, Di, et al.
Publicado: (2021)

Corrigendum: MicroRNA-138-5p Suppresses Non-small Cell Lung Cancer Cells by Targeting PD-L1/PD-1 to Regulate Tumor Microenvironment
por: Song, Nannan, et al.
Publicado: (2020)

Comprehensive Analysis of Ferroptosis Regulators With Regard to PD-L1 and Immune Infiltration in Clear Cell Renal Cell Carcinoma
por: Wang, Song, et al.
Publicado: (2021)

A Combined Two-mRNA Signature Associated With PD-L1 and Tumor Mutational Burden for Prognosis of Lung Adenocarcinoma
por: Song, Congkuan, et al.
Publicado: (2021)

Bridging the Gap: Connecting the Mechanisms of Immune-Related Adverse Events and Autoimmunity Through PD-1
por: Mor, Adam, et al.
Publicado: (2022)

MiR-665 Regulates Vascular Smooth Muscle Cell Senescence by Interacting With LncRNA GAS5/SDC1
por: Chen, Tianbin, et al.
Publicado: (2021)

CARD-Associated Risk Score Features the Immune Landscape and Predicts the Responsiveness to Anti-PD-1 Therapy in IDH Wild-Type Gliomas
por: Li, Depei, et al.
Publicado: (2021)

Phosphorylation of Dynamin-Related Protein 1 (DRP1) Regulates Mitochondrial Dynamics and Skeletal Muscle Wasting in Cancer Cachexia
por: Mao, Xiangyu, et al.
Publicado: (2021)

Immunity-Related Gene Signature Identifies Subtypes Benefitting From Adjuvant Chemotherapy or Potentially Responding to PD1/PD-L1 Blockage in Pancreatic Cancer
por: Qian, Hao, et al.
Publicado: (2021)

Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment
por: Wu, Peijie, et al.
Publicado: (2021)

Targeting Solid Tumors With BTK Inhibitors
por: Uckun, Fatih M., et al.
Publicado: (2021)

Resistance Mechanisms of Anti-angiogenic Therapy and Exosomes-Mediated Revascularization in Cancer
por: Zeng, Ye, et al.
Publicado: (2020)

Androgen Activity Is Associated With PD-L1 Downregulation in Thyroid Cancer
por: O’Connell, Timmy J., et al.
Publicado: (2021)

PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
por: Rose, Maddison, et al.
Publicado: (2020)

Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs
por: Montemagno, Christopher, et al.
Publicado: (2020)

Multi-Omics Analysis of the Anti-tumor Synergistic Mechanism and Potential Application of Immune Checkpoint Blockade Combined With Lenvatinib
por: Lu, Yuting, et al.
Publicado: (2021)

Expanded human NK cells from lung cancer patients sensitize patients’ PDL1−negative tumors to PD1-blockade therapy
por: Poznanski, Sophie M, et al.
Publicado: (2021)

Identification of Prognostic Biomarkers for Multiple Solid Tumors Using a Human Villi Development Model
por: Zhang, Botao, et al.
Publicado: (2020)

Lactobacillus Suppresses Tumorigenesis of Oropharyngeal Cancer via Enhancing Anti-Tumor Immune Response
por: Wang, Ke-Ke, et al.
Publicado: (2022)

NFYA promotes the anti-tumor effects of gluconeogenesis in hepatocellular carcinoma through the regulation of PCK1 expression
por: Tsujimoto, Goki, et al.
Publicado: (2022)

PIP5K1α is Required for Promoting Tumor Progression in Castration-Resistant Prostate Cancer
por: Wang, Tianyan, et al.
Publicado: (2022)

Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond
por: Fazel, Mina, et al.
Publicado: (2023)

Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects
por: Bai, Haiyan, et al.
Publicado: (2023)

PD-L1 Is a Tumor Suppressor in Aggressive Endometrial Cancer Cells and Its Expression Is Regulated by miR-216a and lncRNA MEG3
por: Xu, Daozhi, et al.
Publicado: (2020)

Augmenting the Effectiveness of CAR-T Cells by Enhanced Self-Delivery of PD-1-Neutralizing scFv
por: Ping, Yu, et al.
Publicado: (2020)

Tumor-Associated Extracellular Matrix: How to Be a Potential Aide to Anti-tumor Immunotherapy?
por: He, Yingying, et al.
Publicado: (2021)

p65BTK Is a Novel Biomarker and Therapeutic Target in Solid Tumors
por: Grassilli, Emanuela, et al.
Publicado: (2021)

The ER-Mitochondria Interface as a Dynamic Hub for T Cell Efficacy in Solid Tumors
por: Hunt, Elizabeth G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9c7603sjj7poa61m42satkucng